A 64-year-old man with type 2 diabetes and hypertension has begun to experience generalized weakness. His laboratory results show a serum potassium level of 6.6 mEq/L (reference range, 3.5-5.0). How do you interpret the results?
This randomized clinical trial finds that sodium zirconium cyclosilicate reduced serum potassium levels among ambulatory patients with hyperkalemia.
This open-label randomized trial characterizes reductions in serum potassium levels and adverse events among patients with hyperkalemia and diabetes treated with patiromer, an oral potassium binder.
You currently have no searches saved.